FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809917275> ?p ?o ?g. }

• W2809917275 endingPage "1798" @default.
• W2809917275 startingPage "1791" @default.
• W2809917275 abstract "CYP17 polymorphisms are associated with decreased risk of breast cancer in Chinese Han women: a case-control study Pengtao Yang,1,* Meng Wang,1,* Tian Tian,1,* Yanjing Feng,2 Yi Zheng,1 Tielin Yang,3 Hongtao Li,4 Shuai Lin,1 Peng Xu,1 Yujiao Deng,1 Qian Hao,1 Na Li,1 Feng Guan,5 Zhijun Dai1 1Department of Oncology, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, People’s Republic of China; 2Department of Cardiology, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an 710004, People’s Republic of China; 3School of Life Science and Technology, Xi’an Jiaotong University, Xi’an 710049, People’s Republic of China; 4Department of Breast, Head and Neck Surgery, Affiliated Tumor Hospital of Xinjiang Medical University, Urumchi, 830000, People’s Republic of China; 5College of Life Science and Technology, Northwest University, Xi’an 710069, People’s Republic of China *These authors contributed equally to this work Introduction: CYP17 is the second most important enzyme in estradiol synthesis. Epidemiological studies have shown the associations between CYP17 polymorphisms and cancer risk. We conducted a case–control study to evaluate the relationship between CYP17 polymorphisms (rs743572 and rs2486758) and breast cancer (BC) risk. Patients and methods: This case–control study included 560 BC patients and 583 age-matched healthy controls from Northwest China. Two polymorphisms (rs743572 and rs2486758) of CYP17 were genotyped by using Sequenom MassARRAY. ORs and 95% CIs were used to evaluate the relationship. Results: Compared with the wild genotype of rs743572, we found a significantly reduced risk of BC associated with the variant genotypes (heterozygote model: OR=0.69, 95% CI=0.53–0.89; homozygote model: OR=0.68, 95% CI=0.49–0.95; dominant model: OR=0.69, 95% CI=0.54–0.87; overdominant model: OR=0.78, 95% CI=0.62–0.98; allele model: OR=0.79, 95% CI=0.66–0.93). For rs2486758 polymorphism, we did not find any difference in any of the genetic models. Further stratification analysis by clinical characteristics showed rs743572 was associated with estrogen receptor status (heterozygote model: OR=2.13, 95% CI=1.47–3.08; homozygote model: OR=3.29, 95% CI=1.94–5.58; dominant model: OR=2.39, 95% CI=1.69–3.37) and progesterone receptor status (homozygote model: OR=3.17, 95% CI=1.82–5.55), but there was no association between rs2486758 and clinical characteristics of BC. Haplotype analysis showed that Grs743572Crs2486758 haplotype was a protective factor of BC (OR=0.52, 95% CI=0.40–0.67). Survival analysis did not find that CYP17 rs743572 polymorphism was associated with triple-negative BC, either in terms of overall survival or progression-free survival. Conclusion: Our results suggest that CYP17 polymorphisms may reduce the susceptibility to BC in Chinese women. Keywords: CYP17, polymorphism, breast cancer, susceptibility" @default.
• W2809917275 created "2018-07-10" @default.
• W2809917275 creator A5003957341 @default.
• W2809917275 creator A5008513324 @default.
• W2809917275 creator A5015005766 @default.
• W2809917275 creator A5018283590 @default.
• W2809917275 creator A5024702393 @default.
• W2809917275 creator A5031315906 @default.
• W2809917275 creator A5036726873 @default.
• W2809917275 creator A5047447008 @default.
• W2809917275 creator A5063627915 @default.
• W2809917275 creator A5078356696 @default.
• W2809917275 creator A5081012496 @default.
• W2809917275 creator A5085095982 @default.
• W2809917275 creator A5088074452 @default.
• W2809917275 creator A5090993403 @default.
• W2809917275 date "2018-07-01" @default.
• W2809917275 modified "2023-09-26" @default.
• W2809917275 title "<em>CYP17 </em>polymorphisms are associated with decreased risk of breast cancer in Chinese Han women: a case&ndash;control study" @default.
• W2809917275 cites W123636459 @default.
• W2809917275 cites W1242630251 @default.
• W2809917275 cites W1523277859 @default.
• W2809917275 cites W1969291079 @default.
• W2809917275 cites W1970171759 @default.
• W2809917275 cites W1988411979 @default.
• W2809917275 cites W1998488067 @default.
• W2809917275 cites W2000163529 @default.
• W2809917275 cites W2014415585 @default.
• W2809917275 cites W2043879831 @default.
• W2809917275 cites W2056544643 @default.
• W2809917275 cites W2064658226 @default.
• W2809917275 cites W2094609159 @default.
• W2809917275 cites W2097846180 @default.
• W2809917275 cites W2104800180 @default.
• W2809917275 cites W2117236384 @default.
• W2809917275 cites W2129660385 @default.
• W2809917275 cites W2136650124 @default.
• W2809917275 cites W2141362214 @default.
• W2809917275 cites W2146189706 @default.
• W2809917275 cites W2151032397 @default.
• W2809917275 cites W2153534404 @default.
• W2809917275 cites W2182851752 @default.
• W2809917275 cites W2187181884 @default.
• W2809917275 cites W2272984102 @default.
• W2809917275 cites W2323284402 @default.
• W2809917275 cites W2344268151 @default.
• W2809917275 cites W2347482779 @default.
• W2809917275 cites W2361145805 @default.
• W2809917275 cites W2405817288 @default.
• W2809917275 cites W2409544843 @default.
• W2809917275 cites W2418081881 @default.
• W2809917275 cites W2418845263 @default.
• W2809917275 cites W2464578097 @default.
• W2809917275 cites W2547965941 @default.
• W2809917275 cites W2779341195 @default.
• W2809917275 cites W2781525129 @default.
• W2809917275 cites W912551958 @default.
• W2809917275 doi "https://doi.org/10.2147/cmar.s167503" @default.
• W2809917275 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6037160" @default.
• W2809917275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30013390" @default.
• W2809917275 hasPublicationYear "2018" @default.
• W2809917275 type Work @default.
• W2809917275 sameAs 2809917275 @default.
• W2809917275 citedByCount "10" @default.
• W2809917275 countsByYear W28099172752018 @default.
• W2809917275 countsByYear W28099172752019 @default.
• W2809917275 countsByYear W28099172752020 @default.
• W2809917275 countsByYear W28099172752021 @default.
• W2809917275 countsByYear W28099172752022 @default.
• W2809917275 crossrefType "journal-article" @default.
• W2809917275 hasAuthorship W2809917275A5003957341 @default.
• W2809917275 hasAuthorship W2809917275A5008513324 @default.
• W2809917275 hasAuthorship W2809917275A5015005766 @default.
• W2809917275 hasAuthorship W2809917275A5018283590 @default.
• W2809917275 hasAuthorship W2809917275A5024702393 @default.
• W2809917275 hasAuthorship W2809917275A5031315906 @default.
• W2809917275 hasAuthorship W2809917275A5036726873 @default.
• W2809917275 hasAuthorship W2809917275A5047447008 @default.
• W2809917275 hasAuthorship W2809917275A5063627915 @default.
• W2809917275 hasAuthorship W2809917275A5078356696 @default.
• W2809917275 hasAuthorship W2809917275A5081012496 @default.
• W2809917275 hasAuthorship W2809917275A5085095982 @default.
• W2809917275 hasAuthorship W2809917275A5088074452 @default.
• W2809917275 hasAuthorship W2809917275A5090993403 @default.
• W2809917275 hasBestOaLocation W28099172751 @default.
• W2809917275 hasConcept C104317684 @default.
• W2809917275 hasConcept C121608353 @default.
• W2809917275 hasConcept C126322002 @default.
• W2809917275 hasConcept C135763542 @default.
• W2809917275 hasConcept C143998085 @default.
• W2809917275 hasConcept C144024400 @default.
• W2809917275 hasConcept C146304588 @default.
• W2809917275 hasConcept C149923435 @default.
• W2809917275 hasConcept C166957645 @default.
• W2809917275 hasConcept C191935318 @default.
• W2809917275 hasConcept C205649164 @default.
• W2809917275 hasConcept C29456083 @default.
• W2809917275 hasConcept C530470458 @default.

• next